HER2 in-Situ hybridization positive breast cancers with HER2/CEP17 ratio ≥2.0 and average HER2 copy number <4.0 are frequently discordant with HER2 immunohistochemistry results: Implications for potential modification of testing algorithm

被引：0
|
作者：
Livasy, Chad
Johnson, Nicole
Domfeh, Akosua
机构：
[1] Univ N Carolina, Chapel Hill, NC USA
[2] Levine Canc Inst, Charlotte, NC USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-20-08
引用
收藏
页数：1
相关论文
共 50 条
  • [21] HER2 Testing by FISH: Discordance between HER2 Signals Per Cell and HER2:CEP 17 Ratio
    Dintzis, S. M.
    Allison, K. H.
    Schmidt, R. A.
    CANCER RESEARCH, 2010, 70
  • [22] HER2 status in gastric/gastro-oesophageal junctional cancers: should determination of gene amplification by SISH use HER2 copy number or HER2: CEP17 ratio?
    Kumarasinghe, Marian Priyanthi
    de Boer, Willem Bastiaan
    Khor, Tze Sheng
    Ooi, Esther M.
    Jene, Nic
    Jayasinghe, Sureshini
    Fox, Stephen B.
    PATHOLOGY, 2014, 46 (03) : 184 - 187
  • [23] Impact of Chromosome 17 and HER2 Copy Number Variability on HER2 FISH in Breast Cancer Cases with CEP17 Copy Number Alterations
    Donaldson, Alana R.
    Shetty, Shashirekha
    Rivera, Christine
    Portier, Bryce P.
    Cook, James R.
    Budd, G. T.
    Downs-Kelly, Erinn
    Klein, Roger D.
    Lanigan, Christopher P.
    Tubbs, Raymond
    Calhoun, Benjamin C.
    LABORATORY INVESTIGATION, 2016, 96 : 40A - 41A
  • [24] Impact of Chromosome 17 and HER2 Copy Number Variability on HER2 FISH in Breast Cancer Cases with CEP17 Copy Number Alterations
    Donaldson, Alana R.
    Shetty, Shashirekha
    Rivera, Christine
    Portier, Boyce P.
    Cook, James R.
    Budd, G. T.
    Downs-Kelly, Erinn
    Klein, Roger D.
    Lanigan, Christopher P.
    Tubbs, Raymond
    Calhoun, Benjamin C.
    MODERN PATHOLOGY, 2016, 29 : 40A - 41A
  • [25] Discordance between HER2 Copies/Cell and HER2/CEP17 Ratio by Fluorescence In Situ Hybridization (FISH) in Invasive Breast Carcinoma
    Czapla, A.
    Silverman, J. F.
    Krishnamurti, U.
    MODERN PATHOLOGY, 2014, 27 : 43A - 43A
  • [26] Discordance between HER2 Copies/Cell and HER2/CEP17 Ratio by Fluorescence In Situ Hybridization (FISH) in Invasive Breast Carcinoma
    Czapla, A.
    Silverman, J. F.
    Krishnamurti, U.
    LABORATORY INVESTIGATION, 2014, 94 : 43A - 43A
  • [27] Clinical and Pathologic Features Associated with Invasive Breast Carcinoma with 2018 ASCO/CAP Group ISH 2 Results (HER2/CEP17 ratio ≥2.0 and Average HER2 Copy Number of &lt;4.0)
    Hoda, Raza
    McIntire, Patrick
    Komforti, Miglena
    Downs-Kelly, Erinn
    MODERN PATHOLOGY, 2021, 34 (SUPPL 2) : 111 - 113
  • [28] Clinical and Pathologic Features Associated with Invasive Breast Carcinoma with 2018 ASCO/CAP Group ISH 2 Results (HER2/CEP17 ratio ≥2.0 and Average HER2 Copy Number of &lt;4.0)
    Hoda, Raza
    McIntire, Patrick
    Komforti, Miglena
    Downs-Kelly, Erinn
    LABORATORY INVESTIGATION, 2021, 101 (SUPPL 1) : 111 - 113
  • [29] High HER2 signals and HER2/CEP17 ratio tumours achieve better responses in breast cancer
    Exposito Afonso, I. J.
    del Pino Sedeno, T.
    Gonzalez Villa, I.
    Loro Ferrer, J. F.
    Cabrera Galvan, J. J.
    VIRCHOWS ARCHIV, 2020, 477 : S45 - S46
  • [30] HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer
    Kim, Ji-Won
    Kim, Jee Hyun
    Im, Seock-Ah
    Kim, Yu Jung
    Han, Hye-Suk
    Kim, Jin-Soo
    Lee, Kyung-Hun
    Kim, Tae-Yong
    Han, Sae-Won
    Jeon, Yoon Kyung
    Oh, Do-Youn
    Kim, Tae-You
    Park, In Ae
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (01) : 109 - 115
12345